New vax? Yawn.
No.
I will not take it.
I don’t trust them anymore.
NO THANKS.
Was it even tested?
Hmmmmm ...
Another “vaccine”?
What’s that word I’m looking for?
Ahh!
How about “NO!!!”
“RSV is a common respiratory virus that primarily infects the lungs, nose, throat, and breathing passages. It typically causes mild cold-like symptoms such as a runny nose, fever, cough, and wheezing.”
We need such extreme measures to combat mild symptoms?
We a such a wuss society now.
I don’t trust vaccines anymore. Fool me once... No fooling me twice.
“safe and effective” - just like those showers at Auschwitz.
RSV isn’t too much of a concern for young adults, but can be for older adults. It is extremely dangerous for infants. My grandson was hospitalized and almost died from it.
No thanks. I have ZERO faith and ZERO trust in the FDA, CDC nor any other governmental or quasi-governmental institute-especially when they are telling to me to inject a vaccine into my body.
Pharmaceutical industrial complex at it again. I look forward to the day that nobody ever asks for proof of vaccine (including schools)…at least I can get a religious waiver but even that is an unnecessary burden.
“Vaccine” and “immunization” mean one and done. Is that what this is or will we be treated to an annual “update” campaign?
Y’all can take my place in the queue.
Nope
US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Download (PDF, 224.9KB)
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1
Clinical development programme continues to evaluate safety and immunogenicity in adults 18+ with data read-outs expected H2 2024
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.
US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
Download (PDF, 224.9KB)
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes 1
Clinical development programme continues to evaluate safety and immunogenicity in adults 18+ with data read-outs expected H2 2024
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
In the US, the vaccine is currently approved for use in adults aged 60 and older and recommended by CDC/ACIP using shared clinical decision-making.
Nope. I’m 69 years old, and other than a tetanus shot several years ago I haven’t taken any vaccine for over 50 years, and never plan to. If I get RSV or shingles or pneumonia or influenza or even Covid, well, too bad for me. So far I’ve had none of those things. Maybe flu when I was a kid.
I will NEVER get another vaccine. (Except for tetanus)
” It typically causes mild cold-like symptoms such as a runny nose, fever, cough, and wheezing.”
Wow... I better rush and take an experimental mRNA Franken-vaccine.
HARD PASS